Abera Bioscience AB (NGM: ABERA)
Sweden
· Delayed Price · Currency is SEK 3.860
0.00 (0.00%)
At close: Nov 19, 2024
Abera Bioscience AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Other Revenue | 12.6 | 2.52 | 1.79 | 1.18 | 0.76 | 1.5 | Upgrade
|
| Revenue | 12.6 | 2.52 | 1.79 | 1.18 | 0.76 | 1.5 | Upgrade
|
| Revenue Growth (YoY) | - | 41.21% | 51.78% | 55.92% | -49.67% | -25.54% | Upgrade
|
| Gross Profit | 12.6 | 2.52 | 1.79 | 1.18 | 0.76 | 1.5 | Upgrade
|
| Selling, General & Admin | 16.3 | 19.35 | 21.19 | 10.34 | 4.39 | 3.95 | Upgrade
|
| Other Operating Expenses | 0.18 | 0.09 | 0.05 | 0.02 | 0.06 | 0.03 | Upgrade
|
| Operating Expenses | 16.52 | 19.45 | 21.24 | 10.35 | 4.46 | 3.98 | Upgrade
|
| Operating Income | -3.92 | -16.92 | -19.45 | -9.18 | -3.7 | -2.48 | Upgrade
|
| Interest Expense | -0 | -0 | - | -0 | - | - | Upgrade
|
| Interest & Investment Income | 0.08 | 0.08 | 0.01 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 0.12 | 0.12 | 0.06 | 0.01 | 0.06 | 0.01 | Upgrade
|
| Pretax Income | -3.72 | -16.72 | -19.38 | -9.17 | -3.64 | -2.47 | Upgrade
|
| Net Income | -3.72 | -16.72 | -19.38 | -9.17 | -3.64 | -2.47 | Upgrade
|
| Net Income to Common | -3.72 | -16.72 | -19.38 | -9.17 | -3.64 | -2.47 | Upgrade
|
| Shares Outstanding (Basic) | - | 13 | 12 | 10 | 7 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | - | 13 | 12 | 10 | 7 | 2 | Upgrade
|
| Shares Change (YoY) | - | 13.64% | 14.64% | 45.39% | 200.47% | - | Upgrade
|
| EPS (Basic) | - | -1.26 | -1.66 | -0.90 | -0.52 | -1.06 | Upgrade
|
| EPS (Diluted) | - | -1.26 | -1.66 | -0.90 | -0.52 | -1.06 | Upgrade
|
| Free Cash Flow | -8.53 | -17.71 | -19.69 | -9.68 | -2.75 | -2.99 | Upgrade
|
| Free Cash Flow Per Share | - | -1.33 | -1.69 | -0.95 | -0.39 | -1.28 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -31.10% | -670.22% | -1088.19% | -779.01% | -490.10% | -165.09% | Upgrade
|
| Profit Margin | -29.50% | -662.16% | -1084.01% | -778.09% | -482.12% | -164.62% | Upgrade
|
| Free Cash Flow Margin | -67.68% | -701.43% | -1101.46% | -821.76% | -363.90% | -199.20% | Upgrade
|
| EBIT | -3.92 | -16.92 | -19.45 | -9.18 | -3.7 | -2.48 | Upgrade
|
| EBIT Margin | -31.10% | - | - | - | - | -165.09% | Upgrade
|
| Revenue as Reported | 12.73 | 2.65 | 1.85 | 1.19 | 0.82 | 1.51 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.